1-9 of 9
Johannes Weirather, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Efficacy of Tafasitamab (MOR208) Combined with Lenalidomide in Patients with High-Risk Relapsed or Refractory Diffuse Large B-Cell Lymphoma in the L-Mind Study

Eva González-Barca, MD PhD, Johannes Duell, MD, Federica Cavallo, Juan-Manuel Sancho, MD PhD, Zsolt Nagy, MD PhD, Pau Abrisqueta, MD PhD, Carlos Panizo, MD PhD, Marinela Augustin, Johannes Weirather, PhD, Sumeet Ambarkhane, MD MBBS, Kami J. Maddocks, MD, Nagesh Kalakonda, MD, Gilles Salles, MDPhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 1–2.
https://doi.org/10.1182/blood-2020-140294
Published: 2020
Journal Articles

Long-Term Subgroup Analyses from L-Mind, a Phase II Study of Tafasitamab (MOR208) Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Kami J. Maddocks, MD, Johannes Duell, MD, Eva González-Barca, MD PhD, Wojciech Jurczak, Anna Marina Liberati, MD, Sven de Vos, MD PhD, Zsolt Nagy, MD PhD, Aleš Obr, MDPhD, Gianluca Gaidano, Pau Abrisqueta, MD PhD, Marc André, MD, Martin Dreyling, MD, Tobias F Menne, MD PhD FRCPath, Maren Dirnberger-Hertweck, PhD, Johannes Weirather, PhD, Sumeet Ambarkhane, MD MBBS, Gilles Salles, MDPhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 19–21.
https://doi.org/10.1182/blood-2020-140314
Published: 2020
Journal Articles

Primary Analysis of Anti-CD19 Tafasitamab (MOR208) Treatment in Combination with Idelalisib or Venetoclax in R/R CLL Patients Who Failed Prior BTK Inhibitor Therapy (COSMOS Trial)

Philipp Bernhard Staber, MD PhD, Wojciech Jurczak, Wolfram Brugger, Asher A. Chanan-Khan, MD, Richard Greil, MD, Andrzej Hellmann, MD PhD, Maren Dirnberger-Hertweck, PhD, Peter Kelemen, Jan Moritz Middeke, MD, Marco Montillo, MD, Marina Motta, MD, Talha Munir, MD, Peter Neumeister, MD, Dietger Niederweiser, MD, Sameer A. Parikh, MD, Johannes Schetelig, MDMSc, Stephan Stilgenbauer, Vladan Vucinic, MD, Johannes Weirather, PhD, Jennifer Woyach, MD, Clemens-Martin Wendtner
Journal: Blood
Blood (2019) 134 (Supplement_1): 1754.
https://doi.org/10.1182/blood-2019-128388
Published: 2019
Journal Articles

Subgroup Analyses from L-Mind, a Phase II Study of Tafasitamab (MOR208) Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Johannes Duell, MD, Kami J. Maddocks, MD, Eva González-Barca, MD PhD, Wojciech Jurczak, MD PhD, Anna Marina Liberati, Sven de Vos, MD PhD, Zsolt Nagy, MD PhD, Aleš Obr, MD PhD, Gianluca Gaidano, MD PhD, Pau Abrisqueta, MD PhD, Marc André, Martin Dreyling, MD, Tobias F Menne, MD PhD FRCPath, Maren Dirnberger-Hertweck, PhD, Johannes Weirather, PhD, Sumeet Ambarkhane, MD MBBS, Gilles A. Salles, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1582.
https://doi.org/10.1182/blood-2019-122573
Published: 2019
Journal Articles

A Phase IIa, Open-Label, Multicenter Study of Single-Agent Tafasitamab (MOR208), an Fc-Optimized Anti-CD19 Antibody, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma: Long-Term Follow-up, Final Analysis

Wojciech Jurczak, MD PhD, Pier Luigi Zinzani, MD PhD, Georg Hess, Gianluca Gaidano, MD PhD, Mariano Provencio, MD, Zsolt Nagy, MD PhD, Tadeusz Robak, MD, Kami J. Maddocks, MD, Christian Buske, MD PhD, Sumeet Ambarkhane, MD MBBS, Wolfram Brugger, Maren Dirnberger-Hertweck, PhD, Sascha Tillmanns, Johannes Weirather, PhD, Kristie Blum
Journal: Blood
Blood (2019) 134 (Supplement_1): 4078.
https://doi.org/10.1182/blood-2019-124297
Published: 2019
Journal Articles

Two-Cohort Phase II Study in R/R CLL (COSMOS): First Preliminary Safety and Efficacy Results of Anti-CD19 MOR208 Treatment in Combination with Venetoclax in Patients Who Discontinued Prior BTK Inhibitor Therapy

Philipp Bernhard Staber, MD PhD, Asher A. Chanan-Khan, MD, Talha Munir, Dietger Niederweiser, Johannes Schetelig, MD MSc, Jan Moritz Middeke, MD, Maren Dirnberger-Hertweck, PhD, Peter Kelemen, Johannes Weirather, PhD, Sameer A. Parikh, MD, Stephan Stilgenbauer, MD PhD, Clemens-Martin Wendtner, Jennifer A. Woyach, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4433.
https://doi.org/10.1182/blood-2018-99-114489
Published: 2018
Journal Articles

Single-Arm Phase II Study of MOR208 Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: L-Mind

Gilles Andre Salles, Johannes Duell, MD, Eva González-Barca, MD PhD, Wojciech Jurczak, MDPhD, Anna Marina Liberati, MD, Zsolt Nagy, MD PhD, Aleš Obr, MD, Gianluca Gaidano, MD PhD, Marc Andre, MDPhD, Nagesh Kalakonda, MD, Martin Dreyling, MD PhD, Pier Luigi Zinzani, MD, Maren Dirnberger-Hertweck, PhD, Johannes Weirather, PhD, Sumeet Ambarkhane, MD MBBS, Kami J. Maddocks, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 227.
https://doi.org/10.1182/blood-2018-99-113399
Published: 2018
Journal Articles

Single-Arm Phase II Study of MOR208 Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: L-Mind

Gilles Andre Salles, MD PhD, Johannes Duell, MD, Eva González-Barca, MD PhD, Wojciech Jurczak, PhDMD, Anna Marina Liberati, MD, Zsolt Nagy, MD PhD, Tomáš Papajik, MD PhD, Gianluca Gaidano, MD PhD, Marc Andre, MD, Nagesh Kalakonda, MD, Martin Dreyling, MD PhD, Pier Luigi Zinzani, MD, Sumeet Ambarkhane, MD, Johannes Weirather, PhD, Maren Dirnberger-Hertweck, PhD, Kami J. Maddocks, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 4123.
https://doi.org/10.1182/blood.V130.Suppl_1.4123.4123
Published: 2017
Journal Articles

MOR202, a Human Anti-CD38 Monoclonal Antibody, Mediates Potent Tumoricidal Activity In Vivo and Shows Synergistic Efficacy in Combination with Different Antineoplastic Compounds

Rainer Boxhammer, Johannes Weirather, PhD, Stefan Steidl, PhD, Jan Endell, PhD
Journal: Blood
Blood (2015) 126 (23): 3015.
https://doi.org/10.1182/blood.V126.23.3015.3015
Published: 2015